Cabergoline as an Adjunct to Ovulation Induction in Infertile Women with Endometriosis

Cabergoline as an Adjunct to Ovulation Induction in Infertile Women with Endometriosis: An Open-label Randomized Study - ENDOCAB001

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063714

Enrollment

Registered

2024-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N809- Endometriosis, unspecified

Interventions

Intervention1: Tablet Cabergoline with Tablet Letrozole: Tab. Cabergoline (0.5 MG) 1 Tablet Twice a week with Tab. Letrozole (5 MG) Once a day for 5 Days Control Intervention1: Letrozole: 5mg Once a d

Eligibility

Inclusion criteria

Inclusion criteria: Infertile women with clinically diagnosed endometriosis, with patent tubes, AMH level more than 1.5, AFC count more than 6, husband semen analysis within normal limits

Exclusion criteria

Exclusion criteria: BMI more than 35, compromised tubal function or bilateral tubal block, moderate to severe male factor infertility, grade 3,4 endometriosis, chronic inflammatory disorders, history of allergy to any study drugs, patients with decreased ovarian reserve

Design outcomes

Primary

Measure	Time frame
Ovulation rateTimepoint: 1, 2, 3, 4 cycles	—

Secondary

Measure	Time frame
Cummulative pregnancy rateTimepoint: 4 months;endometrial thicknessTimepoint: 1,2,3,4;incidence of dysmenorrhea and dyspareunia by visual analog scaleTimepoint: 1,2,3,4;pretreatment im]nflammatory markers with ovulation and pregnancy rateTimepoint: 1,4	—

Countries

India

Contacts

Public ContactDr Krutika Dave

AIIMS

garimakachhawa2012@gmail.com9868246702

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026